MFH
MCID: MLG084
MIFTS: 63

Malignant Fibrous Histiocytoma (MFH)

Categories: Bone diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Malignant Fibrous Histiocytoma

MalaCards integrated aliases for Malignant Fibrous Histiocytoma:

Name: Malignant Fibrous Histiocytoma 12 74 52 54 15
Undifferentiated Pleomorphic Sarcoma 52 58 6 17
Ups 52 58
Malignant Fibrohistiocytic Tumors 52
Histiocytoma, Fibrous, Malignant 39
Histiocytoma, Malignant Fibrous 43
Fibroxanthosarcoma 12
Mfh 12

Characteristics:

Orphanet epidemiological data:

58
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

Disease Ontology 12 DOID:1907
MeSH 43 D051677
NCIt 49 C4247
SNOMED-CT 67 34360000 443439001
MESH via Orphanet 44 D051677
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0334463
Orphanet 58 ORPHA2023
UMLS 71 C0334463

Summaries for Malignant Fibrous Histiocytoma

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 2023 Definition An aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis . Epidemiology UPS ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8-1 new case per 100000 per year in one European series. Clinical description The tumor arises most commonly during the sixth and seventh decades of life. The most common sites of involvement include lower extremities (mainly thigh) followed by upper arms, retroperitoneum, viscera, head and neck (in childhood). Primary osseous UPS most commonly occurs in distal femur, proximal tibia, proximal femur and humerus. Patients may present pain, swelling / mass and pathological fractures. In the skin, UPS presents as a relatively painless, rapidly enlarging nodule. Anorexia, malaise, fever and weight loss are present in retroperitoneal and inflammatory forms of UPS. Most UPS recur locally; distant metastases are common (the most frequent is lung). Regional metastases are rare. Etiology UPS is thought to be derived from a primitive mesenchymal cell capable of differentiating into histiocytes, fibroblasts , myofibroblasts and osteoclasts. The etiology of the tumor remains unknown. Prior radiation therapy is a likely risk factor in some cases. Diagnostic methods Any tumor mass over 5 cm is suspected to be a sarcoma. Magnetic resonance imaging (MRI) is the imaging method of choice for limbs and shows a high signal on T2 weighted images. Histology of biopsy specimen prior to any treatment is crucial to reach diagnosis and shows pleomorphic spindle cell population with large atypical cells frequently exhibiting numerous irregular mitotic figures, associated regions of hemorrhage and necrosis, associated lymphohistiocytic infiltrate and invasion of dermis. Immunohistochemical staining is negative for S-100, HMB-45, CD34 and cytokeratin which assists in ruling out other soft tissue tumors. Most cases previously diagnosed as malignant fibrous histiocytoma have been reclassified into other histological types of sarcoma. Differential diagnosis When occurring in skin, UPS is difficult to differentiate from atypical fibroxanthoma or dermatofibrosarcoma protuberans (see this term). Histological differential diagnoses include leiomyosarcoma, rhabdomyosarcoma, lymphoma, and melanoma (see these terms). Management and treatment UPS should be referred to an expert/ reference center for primary biopsy, expert pathology review, and multidisciplinary treatment. Immediate surgery of a mass without knowledge of its histological nature is strongly discouraged because it is associated with an increased risk of death due to inappropriate resection and increased risk of relapse. UPS is best treated by wide surgical excision. Sometimes amputation may be necessary to remove the whole lesion. Adjuvant radiotherapy is given for high-grade, large (>5 cm), deep-seated tumors, in limb sparing surgeries and when negative margins are not obtained. For non-operable sarcomas, primary radiation therapy could be an option, but usually doxorubicin containing regimens are preferred options in first-line setting for locally irresectable and/or metastatic lesions. Chemotherapy (CHT) with ifosfamide, trabectedin, dacarbazine, pazopanib have demonstrated efficacy in UPS and are registered and available in most European Union countries. Prognosis A 5-year overall survival rate of 48% has been reported for patients with head and neck tumors versus 77% for patients with tumors arising on the trunk and extremities. The childhood variant appears have better prognosis. Visit the Orphanet disease page for more resources.

MalaCards based summary : Malignant Fibrous Histiocytoma, also known as undifferentiated pleomorphic sarcoma, is related to malignant fibrous histiocytoma of bone and soft tissue sarcoma. An important gene associated with Malignant Fibrous Histiocytoma is RECQL4 (RecQ Like Helicase 4), and among its related pathways/superpathways are Striated Muscle Contraction and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Dactinomycin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are abnormality of the lower limb and abnormality of the peritoneum

Wikipedia : 74 Undifferentiated pleomorphic sarcoma, previously malignant fibrous histiocytoma, is a type of cancer,... more...

Related Diseases for Malignant Fibrous Histiocytoma

Diseases in the Fibrous Histiocytoma family:

Malignant Fibrous Histiocytoma Malignant Inflammatory Fibrous Histiocytoma

Diseases related to Malignant Fibrous Histiocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 5702)
# Related Disease Score Top Affiliating Genes
1 malignant fibrous histiocytoma of bone 34.7 SERPINA3 MYOD1 DES
2 soft tissue sarcoma 32.2 MDM2 EWSR1
3 retroperitoneal fibrosis 31.9 VIM PTPRC MDM2
4 infantile myofibromatosis 31.9 VIM PDGFRB DES ACTC1
5 myxofibrosarcoma 31.8 SERPINA3 MYOG MUC1 MTAP MDM2 EWSR1
6 rare tumor 31.8 EWSR1 DES ACTC1
7 malignant triton tumor 31.7 MYOG MYOD1 DES
8 fibrosarcoma 31.6 VIM EWSR1 DES ACTC1
9 fibrous histiocytoma 31.4 VIM SERPINA3 MYOG MTAP MFHAS1 F13A1
10 secretory meningioma 31.3 VIM SERPINA3 MUC1
11 bone sarcoma 31.2 SERPINA3 MTAP MDM2 EWSR1
12 lung sarcoma 31.0 SERPINA3 EWSR1
13 malignant giant cell tumor 31.0 CD68 ACTC1
14 spindle cell carcinoma 31.0 VIM MUC1 DES ACTC1
15 familial retinoblastoma 31.0 RECQL4 MDM2 CDK4
16 epithelioid sarcoma 31.0 VIM MUC1 CD68
17 retroperitoneal sarcoma 30.9 MYOG MDM2 EWSR1 CDK4
18 ring chromosome 30.9 MDM2 EWSR1 CDK4
19 xanthogranulomatous pyelonephritis 30.9 SERPINA3 CD68
20 vulvar sarcoma 30.9 EWSR1 ACTC1
21 myxoid liposarcoma 30.8 MDM2 EWSR1 DDIT3 CDK4
22 mesenchymal cell neoplasm 30.8 SERPINA3 PDGFRB MYOG EWSR1 CD68
23 inflammatory leiomyosarcoma 30.8 MYOG DES
24 spindle cell sarcoma 30.8 VIM SERPINA3 MYOG MUC1 MDM2 DES
25 lymphangioma 30.7 VIM SERPINA3 ACTC1
26 heart sarcoma 30.7 MYOG MDM2
27 angiosarcoma 30.7 VIM MYOG MUC1 MDM2 CD68
28 neurofibroma 30.7 VIM MUC1 F13A1 ACTC1
29 chordoma 30.7 VIM SERPINA3 PDGFRB MUC1 MTAP DES
30 myxoid chondrosarcoma 30.7 MUC1 MTAP EWSR1 CD68
31 granular cell tumor 30.6 VIM SERPINA3 DES CD68
32 carcinosarcoma 30.6 VIM MUC1 DES ACTC1
33 malignant mesenchymoma 30.6 SERPINA3 MYOG MYOD1 MDM2 DES
34 malignant inflammatory fibrous histiocytoma 30.6 SERPINA3 MDM2 CDK4 CD68
35 sarcomatoid squamous cell skin carcinoma 30.6 SERPINA3 CD68
36 pleomorphic lipoma 30.6 SERPINA3 MDM2 CDK4 CD68
37 malignant granular cell myoblastoma 30.6 SERPINA3 CD68
38 benign ependymoma 30.6 VIM MUC1 MDM2
39 fibrous meningioma 30.6 VIM MUC1 F13A1
40 desmoid tumor 30.6 PDGFRB DES ACTC1
41 fibromatosis 30.6 VIM DES ACTC1
42 extraosseous osteosarcoma 30.6 MYOG MDM2 CDK4 CD68
43 neurilemmoma 30.5 VIM SERPINA3 PDGFRB MUC1 DES ACTC1
44 connective tissue cancer 30.5 SERPINA3 MDM2 EWSR1 CDK4
45 interdigitating dendritic cell sarcoma 30.5 SERPINA3 CD68
46 liver sarcoma 30.5 SERPINA3 MYOG CD68
47 chondrosarcoma 30.5 VIM SERPINA3 MUC1 MTAP MDM2 EWSR1
48 pleomorphic rhabdomyosarcoma 30.5 MYOG MYOD1 ACTC1
49 epulis 30.4 VIM SERPINA3 DES CD68
50 pneumothorax 30.4 VIM MUC1 ACTC1

Graphical network of the top 20 diseases related to Malignant Fibrous Histiocytoma:



Diseases related to Malignant Fibrous Histiocytoma

Symptoms & Phenotypes for Malignant Fibrous Histiocytoma

Human phenotypes related to Malignant Fibrous Histiocytoma:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the lower limb 58 31 hallmark (90%) Very frequent (99-80%) HP:0002814
2 abnormality of the peritoneum 58 31 hallmark (90%) Very frequent (99-80%) HP:0002585
3 soft tissue sarcoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0030448
4 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
5 abnormality of the musculature 58 31 frequent (33%) Frequent (79-30%) HP:0003011
6 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
7 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
8 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
9 abnormality of the upper limb 58 31 occasional (7.5%) Occasional (29-5%) HP:0002817
10 abnormal test result 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Malignant Fibrous Histiocytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDK4 DDIT3 DES F13A1 MDM2 PTPRC

MGI Mouse Phenotypes related to Malignant Fibrous Histiocytoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ACTC1 CDK4 DDIT3 DES F13A1 HSPB2
2 cellular MP:0005384 10 ACTC1 CDK4 DDIT3 DES HSPB2 MDM2
3 homeostasis/metabolism MP:0005376 9.97 ACTC1 CDK4 DDIT3 DES EREG F13A1
4 muscle MP:0005369 9.56 ACTC1 CDK4 DES MDM2 MYOD1 MYOG
5 neoplasm MP:0002006 9.17 CDK4 DDIT3 EREG MDM2 MYOD1 PTPRC

Drugs & Therapeutics for Malignant Fibrous Histiocytoma

Drugs for Malignant Fibrous Histiocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
2
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
3
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Epirubicin Approved Phase 3 56420-45-2 41867
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
9
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
11 Olaratumab Approved, Investigational Phase 3 1024603-93-7
12
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
13
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
14
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
15
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
16 Etoposide phosphate Phase 3
17 Tubulin Modulators Phase 3
18 Antimitotic Agents Phase 3
19
Isophosphamide mustard Phase 2, Phase 3 0
20 Alkylating Agents Phase 2, Phase 3
21 Anti-Bacterial Agents Phase 2, Phase 3
22 Antibiotics, Antitubercular Phase 2, Phase 3
23
Liposomal doxorubicin Phase 2, Phase 3 31703
24
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
25
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
29
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
30
leucovorin Approved Phase 2 58-05-9 6006 143
31
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
32
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
33
Bevacizumab Approved, Investigational Phase 2 216974-75-3
34
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
35
Melphalan Approved Phase 2 148-82-3 460612 4053
36
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
37
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
40
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
41
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
42
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
43
Ipilimumab Approved Phase 2 477202-00-9
44
nivolumab Approved Phase 2 946414-94-4
45
Pembrolizumab Approved Phase 2 1374853-91-4
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
48
Mesna Approved, Investigational Phase 2 3375-50-6 598
49
Durvalumab Approved, Investigational Phase 2 1428935-60-7
50
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
4 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
6 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
7 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
8 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
12 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
13 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
14 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
15 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
16 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
17 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
19 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
20 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
21 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
22 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
23 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
24 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
25 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
26 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
27 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
28 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
29 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
30 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
31 Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) Completed NCT00085475 Phase 2 imatinib mesylate
32 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
33 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
34 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
36 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
37 A Study of Bevacizumab, a Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma Completed NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
38 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
39 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2
40 SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity Recruiting NCT03092323 Phase 2 Pembrolizumab
41 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Recruiting NCT03899805 Phase 2 Eribulin;Pembrolizumab
42 A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma Recruiting NCT04332874 Phase 2 Pembrolizumab;infusion of melphalan and dactinomycin
43 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Recruiting NCT02923778 Phase 2
44 A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
45 A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma Recruiting NCT04356872 Phase 2 Sintilimab;Doxorubicin Hydrochloride;Ifosfamide
46 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
47 A Phase 1b Single Center Investigation of Safety/Efficacy of Nivolumab (Opdivo®) and ABI-009 (Nab-rapamycin) in Patients With Advanced Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Chondrosarcoma, Osteosarcoma and Ewing Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
48 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
49 Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas Recruiting NCT03277924 Phase 1, Phase 2 Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent];Nivolumab 100 MG/10 ML [Opdivo]
50 Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Recruiting NCT03989596 Phase 2

Search NIH Clinical Center for Malignant Fibrous Histiocytoma

Cochrane evidence based reviews: histiocytoma, malignant fibrous

Genetic Tests for Malignant Fibrous Histiocytoma

Anatomical Context for Malignant Fibrous Histiocytoma

MalaCards organs/tissues related to Malignant Fibrous Histiocytoma:

40
Bone, Lung, Breast, Skin, Heart, Liver, Kidney

Publications for Malignant Fibrous Histiocytoma

Articles related to Malignant Fibrous Histiocytoma:

(show top 50) (show all 4073)
# Title Authors PMID Year
1
Transarterial catheter embolization of a sarcoma for preoperative conditioning. 61 54
20464676 2010
2
Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. 54 61
20368975 2010
3
Malignant fibrous histiocytoma--pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study. 61 54
19159951 2010
4
Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. 61 54
17229543 2007
5
High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors. 54 61
16740036 2006
6
[Malignant fibrous histiocytoma: pleomorphic sarcoma NOS or pleomorphic fibrosarcoma]. 54 61
15702318 2005
7
Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma. 61 54
16047946 2005
8
[Gastrointestinal stromal tumor: a clinicopathological study of 74 cases]. 61 54
15796874 2005
9
Dermatofibrosarcoma protuberans--an update. 61 54
16279228 2004
10
Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. 61 54
15277221 2004
11
Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. 61 54
15221942 2004
12
Expression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 cases. 54 61
15188137 2004
13
The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. 61 54
15174563 2004
14
Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. 54 61
15274392 2004
15
The expression of selected immunocytochemical diagnostic markers in the case of chondrosarcoma with a mesenchymal component. 54 61
14655155 2003
16
Anaplastic lymphoma kinase negative sarcomatoid variant of anaplastic large-cell lymphoma presenting as a malignant fibrous histiocytoma. 54 61
12799899 2003
17
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 54 61
12640106 2003
18
Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. 61 54
12181274 2002
19
Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. 54 61
11688574 2001
20
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. 61 54
11555609 2001
21
Connective tissue growth factor expression in pediatric myofibroblastic tumors. 61 54
11200489 2001
22
Primary cardiac malignant fibrous histiocytoma in the right ventricular infundibulum treated with a cavo-pulmonary shunt and coronary embolization. 61 54
11194295 2000
23
Locus-specific multifluor FISH analysis allows physical characterization of complex chromosome abnormalities in neoplasia. 61 54
10862042 2000
24
Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. 54 61
10628802 1999
25
Differential expression of connective tissue growth factor gene in cutaneous fibrohistiocytic and vascular tumors. 54 61
9550312 1998
26
Factor XIIIa-immunoreactivity in tumors of the central nervous system. 61 54
9561329 1998
27
Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma. 61 54
9640970 1998
28
MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. 61 54
8919547 1996
29
[Pulmonary malignant fibrous histiocytoma treated with cisplatin plus etoposide followed by surgery]. 54 61
8538096 1995
30
Prognostic relevance of Ki-67 antigen and c-myc oncoprotein in malignant fibrous histocytoma. 54 61
8572578 1995
31
Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. 54 61
8625155 1995
32
Enhanced expression of catalytic subunit isoform PP1 gamma 1 of protein phosphatase type 1 in malignant fibrous histiocytoma. 61 54
7850251 1994
33
Malignant fibrous histiocytoma in chordoma--immunohistochemical evidence of transformation from chordoma to malignant fibrous histiocytoma. 61 54
8091802 1994
34
Hsp27 expression in neuroblastoma: correlation with disease stage. 54 61
8169976 1994
35
No rearrangements of the CHOP gene in malignant fibrous histiocytoma. 54 61
8143276 1994
36
Prognostic influence of HSP-27 expression in malignant fibrous histiocytoma: a clinicopathological and immunohistochemical study. 61 54
1313743 1992
37
Platelet-derived growth factor receptor (beta-subunit) immunoreactivity in soft tissue tumors. 54 61
1309926 1992
38
Evaluation of CD68 and other histiocytic antigens in angiomatoid malignant fibrous histiocytoma. 61 54
1676879 1991
39
Cell marker studies in undifferentiated soft tissue sarcoma. 61 54
1752649 1991
40
Congenital, infiltrating giant-cell angioblastoma. A new entity? 54 61
1989466 1991
41
Comparative immunohistochemistry of malignant fibrous histiocytoma and sarcomatoid carcinoma of the urinary tract. 54 61
1851349 1991
42
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. 61 54
2260621 1990
43
Immunohistochemical study of 4-hydroxyaminoquinoline 1-oxide-induced rat malignant fibrous histiocytoma. 61 54
2158461 1990
44
Radiation-Associated Laryngeal Malignant Fibrous Histiocytoma. 61
31046455 2020
45
The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions. 61
32127249 2020
46
A Genomic Survey of Sarcomas on Sun-Exposed Skin Reveals Distinctive Candidate Drivers and Potentially Targetable Mutations. 61
32540221 2020
47
SKP2 My Lou, My Darling. 61
32540853 2020
48
Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. 61
32127392 2020
49
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival. 61
32161142 2020
50
The long non-coding RNA NEAT1 promotes sarcoma metastasis by regulating RNA splicing pathways. 61
32561656 2020

Variations for Malignant Fibrous Histiocytoma

ClinVar genetic disease variations for Malignant Fibrous Histiocytoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RECQL4 NM_004260.3(RECQL4):c.1717C>T (p.Gln573Ter)SNV Pathogenic 620609 rs1483085748 8:145739734-145739734 8:144514350-144514350

Cosmic variations for Malignant Fibrous Histiocytoma:

9 (show top 50) (show all 649)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM101976974 XPO1 soft tissue,lower extremity,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 6
2 COSM87949760 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.871A>C p.K291Q 17:7673749-7673749 6
3 COSM87900565 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 6
4 COSM87906877 TP53 soft tissue,bone,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 6
5 COSM87897745 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 6
6 COSM87912393 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 6
7 COSM87911884 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.856G>T p.E286* 17:7673764-7673764 6
8 COSM88205650 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.611A>G p.E204G 17:7674920-7674920 6
9 COSM87900604 TP53 soft tissue,NS,rhabdomyosarcoma,spindle cell c.637C>T p.R213* 17:7674894-7674894 6
10 COSM87918666 TP53 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 6
11 COSM87897711 TP53 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 6
12 COSM87938119 TP53 soft tissue,bone,leiomyosarcoma,NS c.512A>G p.E171G 17:7675100-7675100 6
13 COSM87897839 TP53 soft tissue,NS,rhabdomyosarcoma,pleomorphic c.701A>G p.Y234C 17:7674262-7674262 6
14 COSM87967612 TP53 soft tissue,arm,leiomyosarcoma,NS c.652G>A p.V218M 17:7674879-7674879 6
15 COSM87922564 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 6
16 COSM94086664 TOP1 soft tissue,lower extremity,leiomyosarcoma,NS c.1576G>C p.E526Q 20:41114093-41114093 6
17 COSM93617455 SUFU soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.780G>T p.E260D 10:102597163-102597163 6
18 COSM93992510 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
19 COSM84133785 RICTOR soft tissue,NS,rhabdomyosarcoma,pleomorphic c.2898-1G>T p.? 5:38952426-38952426 6
20 COSM86625172 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1004T>G p.L335* 13:48367558-48367558 6
21 COSM86633237 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.345C>G p.F115L 13:48342679-48342679 6
22 COSM93451505 RAC1 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 6
23 COSM96995108 PTPRT soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3415C>T p.R1139W 20:42106818-42106818 6
24 COSM96996279 PTPRT soft tissue,lower extremity,leiomyosarcoma,NS c.1201C>T p.R401W 20:42472515-42472515 6
25 COSM101931022 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 6
26 COSM101978164 PTPRD soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 6
27 COSM96843054 PTEN soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.697C>T p.R233* 10:87957915-87957915 6
28 COSM96842281 PTEN soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.389G>A p.R130Q 10:87933148-87933148 6
29 COSM96879218 PTEN soft tissue,retroperitoneum,leiomyosarcoma,NS c.1027-7T>C p.? 10:87965280-87965280 6
30 COSM90842465 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 6
31 COSM96437477 PIK3CG soft tissue,NS,rhabdomyosarcoma,spindle cell c.2638G>A p.E880K 7:106883041-106883041 6
32 COSM87210160 PIK3CA soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 6
33 COSM87181562 PIK3CA soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 6
34 COSM87146468 PIK3CA soft tissue,retroperitoneum,leiomyosarcoma,NS c.1798G>A p.E600K 3:179219622-179219622 6
35 COSM101270110 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
36 COSM98770048 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 6
37 COSM97687376 NTRK3 soft tissue,NS,rhabdomyosarcoma,spindle cell c.492C>A p.C164* 15:88137534-88137534 6
38 COSM97660893 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1577C>A p.P526Q 15:88032865-88032865 6
39 COSM97675531 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452G>A p.S151N 15:88147347-88147347 6
40 COSM97107943 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 6
41 COSM97107326 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.181C>A p.Q61K 1:114713909-114713909 6
42 COSM97107359 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.182A>G p.Q61R 1:114713908-114713908 6
43 COSM98006136 NOTCH4 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2738C>G p.S913C 6:32210879-32210879 6
44 COSM86198080 NOTCH3 soft tissue,lower extremity,leiomyosarcoma,NS c.2741C>T p.P914L 19:15181627-15181627 6
45 COSM89882601 NKX2-1 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.404G>T p.R135M 14:36519044-36519044 6
46 COSM84820183 MYOD1 soft tissue,NS,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 11:17720147-17720147 6
47 COSM101146422 MYCL soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.740G>A p.R247H 1:39897817-39897817 6
48 COSM94449550 MTOR soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4799A>G p.E1600G 1:11144721-11144721 6
49 COSM85771827 MSH6 soft tissue,lower extremity,leiomyosarcoma,NS c.3991C>T p.R1331* 2:47806641-47806641 6
50 COSM94301542 MPL soft tissue,lower extremity,leiomyosarcoma,NS c.1880T>C p.L627P 1:43352744-43352744 6

Copy number variations for Malignant Fibrous Histiocytoma from CNVD:

7 (show all 41)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18958 1 148000000 153300000 Gain Malignant fibrous histiocytomas
2 27753 1 212100000 222100000 Loss Malignant fibrous histiocytomas
3 33593 1 46500000 56200000 Gain Malignant fibrous histiocytomas
4 35188 1 60900000 69500000 Gain Malignant fibrous histiocytomas
5 37769 1 94500000 99400000 Gain Malignant fibrous histiocytomas
6 39415 10 114900000 121700000 Loss Malignant fibrous histiocytomas
7 50207 11 115400000 134452384 Loss Malignant fibrous histiocytomas
8 59633 11 76700000 85300000 Loss Malignant fibrous histiocytomas
9 60562 11 87900000 96700000 Loss Malignant fibrous histiocytomas
10 69083 12 5300000 14800000 Gain Malignant fibrous histiocytomas
11 76673 13 34700000 48900000 Loss Malignant fibrous histiocytomas
12 78011 13 48900000 57600000 Loss Malignant fibrous histiocytomas
13 86677 14 64000000 88900000 Gain Malignant fibrous histiocytomas
14 88587 14 92800000 106368585 Gain Malignant fibrous histiocytomas
15 101715 16 45500000 54500000 Loss Malignant fibrous histiocytomas
16 103579 16 6300000 10300000 Loss Malignant fibrous histiocytomas
17 107007 17 11200000 15900000 Gain Malignant fibrous histiocytomas
18 107027 17 11200000 22100000 Gain Malignant fibrous histiocytomas
19 107535 17 15900000 22100000 Gain Malignant fibrous histiocytomas
20 112060 17 37800000 44800000 Gain Malignant fibrous histiocytomas
21 119810 18 17300000 23300000 Gain Malignant fibrous histiocytomas
22 122735 18 59800000 76117153 Loss Malignant fibrous histiocytomas
23 127802 19 37100000 47800000 Gain Malignant fibrous histiocytomas
24 134297 2 1 12800000 Loss Malignant fibrous histiocytomas
25 142547 2 225800000 237000000 Loss Malignant fibrous histiocytomas
26 154853 20 49200000 54400000 Gain Malignant fibrous histiocytomas
27 163375 22 27900000 35900000 Gain Malignant fibrous histiocytomas
28 163745 22 30500000 39300000 Gain Malignant fibrous histiocytomas
29 164763 22 39300000 49691432 Loss Malignant fibrous histiocytomas
30 178974 3 83700000 89400000 Gain Malignant fibrous histiocytomas
31 187572 4 52400000 59200000 Gain Malignant fibrous histiocytomas
32 192956 5 121500000 143100000 Loss Malignant fibrous histiocytomas
33 198017 5 18500000 23300000 Gain Malignant fibrous histiocytomas
34 214607 6 63500000 75900000 Gain Malignant fibrous histiocytomas
35 221899 7 147500000 158821424 Loss Malignant fibrous histiocytomas
36 225328 7 4500000 7200000 Gain Malignant fibrous histiocytomas
37 226671 7 61100000 71800000 Gain Malignant fibrous histiocytomas
38 237234 8 2200000 19100000 Loss Malignant fibrous histiocytomas
39 244141 8 93500000 99100000 Gain Malignant fibrous histiocytomas
40 250775 9 2200000 9000000 Loss Malignant fibrous histiocytomas
41 255895 9 86100000 113900000 Gain Malignant fibrous histiocytomas

Expression for Malignant Fibrous Histiocytoma

Search GEO for disease gene expression data for Malignant Fibrous Histiocytoma.

Pathways for Malignant Fibrous Histiocytoma

Pathways related to Malignant Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.99 VIM DES ACTC1
2 10.9 PTPRC MYOG MYOD1 DES

GO Terms for Malignant Fibrous Histiocytoma

Cellular components related to Malignant Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10 VIM SERPINA3 RECQL4 PDGFRB MYOG MYOD1
2 cytoplasm GO:0005737 9.5 VIM RECQL4 PDGFRB MYOD1 MUC1 MTAP
3 transcription factor complex GO:0005667 9.26 MYOG MYOD1 DDIT3 CDK4

Biological processes related to Malignant Fibrous Histiocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to toxic substance GO:0009636 9.58 PDGFRB MDM2 CDK4
2 response to hyperoxia GO:0055093 9.46 PDGFRB CDK4
3 cardiac myofibril assembly GO:0055003 9.43 PDGFRB ACTC1
4 myotube differentiation GO:0014902 9.37 MYOG MYOD1
5 positive regulation of fibroblast proliferation GO:0048146 9.33 PDGFRB EREG CDK4
6 positive regulation of skeletal muscle fiber development GO:0048743 9.32 MYOG MYOD1
7 muscle cell fate commitment GO:0042693 9.26 MYOG MYOD1
8 muscle filament sliding GO:0030049 9.13 VIM DES ACTC1
9 positive regulation of muscle cell differentiation GO:0051149 8.8 MYOG MYOD1 MDM2

Sources for Malignant Fibrous Histiocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....